RecruitingPhase 3NCT07087054

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

Studying Carcinoid syndrome

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Crinetics Pharmaceuticals Inc.
Intervention: Paltusotine(drug)
Enrollment: 141 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2030

Study locations (30)

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
Yale University - New Haven Hospital - Yale Cancer Center, New Haven, Connecticut, United States
Moffitt Cancer Center, Tampa, Florida, United States
Winshop Cancer Institute - Emory University, Atlanta, Georgia, United States
University of Iowa Health Care, Iowa City, Iowa, United States
University of Kentucky Medical Center, Lexington, Kentucky, United States
Louisiana State University Health Sciences, Metairie, Louisiana, United States
Henry Ford Cancer - Detroit, Detroit, Michigan, United States
Mayo Clinic, Rochester, Minnesota, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07087054 on ClinicalTrials.gov

Other trials for Carcinoid syndrome

Additional recruiting or active studies for the same condition.

See all trials for Carcinoid syndrome →

← Back to all trials